---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-032014"
form_type: "8-K"
ticker: "FEMY"
cik: "0001339005"
company_name: "FEMASYS INC"
filed_at: "2025-08-20T23:59:59+00:00"
generated_at: "2026-05-17T11:06:42.223714+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Femasys secures UK MHRA approval for FemBloc permanent birth control

## Summary
- MHRA approval validates safety, quality, and effectiveness for UK market.
- Follows CE mark for Europe; expands global commercialization strategy.
- FemBloc is a non-surgical polymer that forms scar tissue for permanent occlusion.
- UK's NHS offers pathway to broad adoption for innovative women's health solutions.
- Company plans to secure a strategic partner for UK commercialization.

## SEC filing metadata
- accession: 0001140361-25-032014
- form_type: 8-K
- ticker: FEMY
- cik: 0001339005
- company_name: FEMASYS INC
- filed_at: 2025-08-20T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339005/000114036125032014/0001140361-25-032014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339005/000114036125032014/ef20054250_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-032014
- JSON: https://secwatch.observer/filing/0001140361-25-032014.json
- Plain text: https://secwatch.observer/filing/0001140361-25-032014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.